Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
01:49am, Friday, 08'th Dec 2023
I am upgrading Teva Pharmaceutical to "Buy" for 2024, buoyed by opioid litigation resolution and promising drugs like TEV'574. Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, a
Teva Pharma is the way to play the re-rise of generic drugs
06:25am, Tuesday, 28'th Nov 2023
Generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd. NYSE: TEVA stock has underperformed for nearly a decade.
Teva Pharmaceutical analysts boost target price as brand transition underway
03:54pm, Monday, 27'th Nov 2023
Teva Pharmaceutical Industries (NASDAQ:TEVA) Ltd is uniquely positioned to undergo a significant transition to a more brand focused company that should drive outperformance of its stock price, accordi
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
04:30pm, Monday, 20'th Nov 2023
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx
2 overlooked stocks that crushed earnings but traded lower
06:22am, Monday, 20'th Nov 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
11:03am, Thursday, 09'th Nov 2023
TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
12:48pm, Wednesday, 08'th Nov 2023
Teva Pharmaceutical Industries (NYSE:TEVA ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Investor Relations Richard Francis - Pre
Teva shares climb as third-quarter sales top estimates
08:46am, Wednesday, 08'th Nov 2023
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA, -0.11% gained 3% premarket on Wednesday after the company reported third-quarter sales that topped expectations and raised its
Teva Pharm Q3 profit rises, sees higher 2023 revenue
07:40am, Wednesday, 08'th Nov 2023
Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington's Disease, and said production in Israel was unaffected by the cou
Drugmaker Teva does not see big impact on business from Israel-Hamas war
12:31pm, Tuesday, 10'th Oct 2023
Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday.
Israeli Stocks Fall as Investors Fear Middle East Conflict
04:46pm, Monday, 09'th Oct 2023
Two days ago, the Palestinian militant group Hamas launched a full-scale attack on Israel from the Gaza Strip. Since then, a full-scale conflict has escalated with many civilian casualties.
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
08:53am, Monday, 09'th Oct 2023
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
04:30pm, Friday, 06'th Oct 2023
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday
Teva partnership with Sanofi ‘will pay dividends,' analyst says
08:50am, Wednesday, 04'th Oct 2023
Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI an
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drug
03:15am, Wednesday, 04'th Oct 2023
Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately b
